Viral load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading events

  1. Ashish Goyal
  2. Daniel B Reeves
  3. E Fabian Cardozo-Ojeda
  4. Joshua T Schiffer  Is a corresponding author
  5. Bryan T Mayer
  1. Fred Hutchinson Cancer Research Center, United States

Abstract

SARS-CoV-2 is difficult to contain because many transmissions occur during pre-symptomatic infection. Unlike influenza, most SARS-CoV-2 infected people do not transmit while a small percentage infect large numbers of people. We designed mathematical models which link observed viral loads with epidemiologic features of each virus, including distribution of transmissions attributed to each infected person and duration between symptom onset in the transmitter and secondarily infected person. We identify that people infected with SARS-CoV-2 or influenza can be highly contagious for less than one day, congruent with peak viral load. SARS-CoV-2 super-spreader events occur when an infected person is shedding at a very high viral load and has a high number of exposed contacts. The higher predisposition of SARS-CoV-2 towards super-spreading events cannot be attributed to additional weeks of shedding relative to influenza. Rather, a person infected with SARS-CoV-2 exposes more people within equivalent physical contact networks, likely due to aerosolization.

Data availability

The original data and code is shared at: https://github.com/ashish2goyal/SARS_CoV_2_Super_Spreader_Event

Article and author information

Author details

  1. Ashish Goyal

    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States
    Competing interests
    No competing interests declared.
  2. Daniel B Reeves

    Vaccine and Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5684-9538
  3. E Fabian Cardozo-Ojeda

    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States
    Competing interests
    No competing interests declared.
  4. Joshua T Schiffer

    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States
    For correspondence
    jschiffe@fredhutch.org
    Competing interests
    Joshua T Schiffer, Reviewing editor, eLifeIs on the trial planning committee for a Gilead funded trial of remdesivir but is not reimbursed for this activity.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2598-1621
  5. Bryan T Mayer

    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States
    Competing interests
    No competing interests declared.

Funding

National Institute of Allergy and Infectious Diseases (R01 AI121129-05S1)

  • Joshua T Schiffer

Council of State and Territorial Epidemiologists (Inform Public Health Decision Making Funding Opportunity)

  • Joshua T Schiffer

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, Goyal et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 15,114
    views
  • 1,017
    downloads
  • 152
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ashish Goyal
  2. Daniel B Reeves
  3. E Fabian Cardozo-Ojeda
  4. Joshua T Schiffer
  5. Bryan T Mayer
(2021)
Viral load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading events
eLife 10:e63537.
https://doi.org/10.7554/eLife.63537

Share this article

https://doi.org/10.7554/eLife.63537

Further reading

    1. Medicine
    2. Microbiology and Infectious Disease
    3. Epidemiology and Global Health
    4. Immunology and Inflammation
    Edited by Jos WM van der Meer et al.
    Collection

    eLife has published articles on a wide range of infectious diseases, including COVID-19, influenza, tuberculosis, HIV/AIDS, malaria and typhoid fever.

    1. Epidemiology and Global Health
    2. Microbiology and Infectious Disease
    Gillian AM Tarr, Linda Chui ... Tim A McAllister
    Research Article

    Several areas of the world suffer a notably high incidence of Shiga toxin-producing Escherichia coli. To assess the impact of persistent cross-species transmission systems on the epidemiology of E. coli O157:H7 in Alberta, Canada, we sequenced and assembled E. coli O157:H7 isolates originating from collocated cattle and human populations, 2007–2015. We constructed a timed phylogeny using BEAST2 using a structured coalescent model. We then extended the tree with human isolates through 2019 to assess the long-term disease impact of locally persistent lineages. During 2007–2015, we estimated that 88.5% of human lineages arose from cattle lineages. We identified 11 persistent lineages local to Alberta, which were associated with 38.0% (95% CI 29.3%, 47.3%) of human isolates. During the later period, six locally persistent lineages continued to be associated with human illness, including 74.7% (95% CI 68.3%, 80.3%) of reported cases in 2018 and 2019. Our study identified multiple locally evolving lineages transmitted between cattle and humans persistently associated with E. coli O157:H7 illnesses for up to 13 y. Locally persistent lineages may be a principal cause of the high incidence of E. coli O157:H7 in locations such as Alberta and provide opportunities for focused control efforts.